RE:Further pondering on PoNSRichyboy is not easily impressed: "Reading between the lines on the press release, and the webcast, is that they are taking a positive spin on this. Essentially, we are told, all of the data combined will be enough to get approval. That doesn’t impress me."
The Q3 2017 report stated that: "On November 9, 2017, we announced positive results from our registrational clinical trial evaluating the safety and effectiveness of the PoNS device for the treatment of subjects with chronic balance deficits due to mild-to-moderate TBI." Richyboy is accusing the Board of Directors (and the Advisory Board?) of "spin" i.e. deception - serious stuff.
A Y2016's Risk Factor stated that: "If we are unable to complete clinical trials, or are unsuccessful in doing so, we will be unable to advance the PoNS device to regulatory authorization and commericalization ..." This risk was not highlighted in the Q3 report.
It did, however, include mention that funding would be required before 12/31/17 - keep you powder dry.